Pfizer's arthritis contender tofacitinib faces possible US approval delay
This article was originally published in Scrip
Executive Summary
A US FDA approval decision may be delayed for Pfizer's novel, oral JAK-inhibitor tofacitinib - which could give the blockbusters Enbrel (etanercept), Humira (adalimumab) and other TNF-inhibitors a run for their money in the rheumatoid arthritis (RA) market - because the regulator has asked the company for more data.